

Article

Design and syntheses of highly potent teixobactin analogues against *Staphylococcus aureus*, Methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococci (VRE) in vitro and in vivo

Anish Parmar, Rajamani Lakshminarayanan, Abhishek Iyer, Venkatesh Mayandi, Eunice Tze Leng Goh, Daniel G. Lloyd, Madhavi Latha S. Chalasani, Navin Kumar Verma, Stephen H Prior, Roger W Beuerman, Annemieke Madder, Edward J. Taylor, and Ishwar Singh

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.7b01634 • Publication Date (Web): 24 Jan 2018

Downloaded from <http://pubs.acs.org> on January 25, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2 **Design and syntheses of highly potent teixobactin analogues against**
3
4
5 ***Staphylococcus aureus*, Methicillin-resistant *Staphylococcus aureus***
6
7
8 **(MRSA), vancomycin-resistant Enterococci (VRE) *in vitro* and *in vivo***
9

10 Anish Parmar,^{[a]†} Rajamani Lakshminarayanan,^{[b]†} Abhishek Iyer,^{[a][c]} Venkatesh Mayandi,
11
12
13
14 ^[b] Eunice Tze Leng Goh,^[b] Daniel G. Lloyd,^[d], Madhavi Latha S. Chalasani,^[e] Navin K.
15
16 Verma,^{[e][b]} Stephen H. Prior,^[f] Roger W. Beuerman,^[b] Annemieke Madder,^[c] Edward J.
17
18 Taylor,^[d] and Ishwar Singh* ^[a]
19
20
21
22
23

24 ^[a] School of Pharmacy, Joseph Banks Laboratories, University of Lincoln, Green Lane, Lincoln LN6
25
26 7DL, United Kingdom.
27

28 ^[b] Singapore Eye Research Institute, The Academia, Discovery Tower Level 6, 20 College Road
29
30 Singapore 169857
31
32

33 ^[c] Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular
34
35 Chemistry, Ghent University, Krijgslaan 281 (S4), B-9000 Ghent, Belgium
36
37

38 ^[d] School of Life Sciences, Joseph Banks Laboratories, University of Lincoln, Green Lane, Lincoln LN6
39
40 7DL, United Kingdom.
41

42 ^[e] Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921
43

44 ^[f] School of Chemistry, Joseph Banks Laboratories, University of Lincoln, Green Lane, Lincoln LN6
45
46 7DL, United Kingdom.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract: The cyclic depsipeptide, teixobactin kills a number of Gram positive bacteria including Methicillin-resistant *Staphylococcus aureus* (MRSA) and *Mycobacterium tuberculosis* without detectable resistance. To date, teixobactin is the only molecule in its class which has shown *in vivo* antibacterial efficacy. In this work, we designed and synthesized 10 new *in vivo* ready teixobactin analogues. These analogues showed highly potent antibacterial activity against *Staphylococcus aureus*, MRSA, and vancomycin-resistant Enterococci (VRE) *in vitro*. One analogue, D-Arg₄-Leu₁₀-teixobactin **2** was found to be non-cytotoxic *in vitro* and *in vivo*. Moreover, topical instillation of peptide **2** in a mice model of *S. aureus* keratitis decreased the bacterial bioburden (>99.0% reduction) and corneal edema significantly when compared to untreated mice cornea. Collectively, our results have established the high therapeutic potential of a teixobactin analogue in attenuating bacterial infections and associated severities *in vivo*.

Introduction

The increasing bacterial resistance against currently used antibiotics and lack of new antibiotics to combat antimicrobial resistance (AMR) are major challenges to global health and wealth. These major challenges are estimated to cause 10 million deaths every year and \$100 trillion in lost productivity to the global economy by 2050.¹ Therefore, there is a continual need to develop new antibacterial compounds. The recently discovered natural product, teixobactin has shown remarkable activity against a broad range of Gram positive bacteria, including resistant bacterial strains such as Methicillin-resistant *Staphylococcus aureus* (MRSA), *Enterococcus spp.* (vancomycin-resistant enterococci, VRE) and






1
2 *Mycobacterium tuberculosis*.² Teixobactin is a nonribosomal undecapeptide. It contains four
3
4 D amino acids namely *N*-Me-D-Phe₁, D-Gln₄, *D-allo*-Ile₅ and D-Thr₈ and the rare L-allo-
5
6 enduracididine amino acid (Figure 1 A, marked in red and blue respectively). Teixobactin kills
7
8 bacteria without detectable resistance and bacteria are less likely to develop resistance
9
10 because it operates by at least two unique modes of action. Notably, teixobactin binds to the
11
12 highly conserved pyrophosphate motifs of multiple bacterial cell wall substrates such as lipid
13
14 II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid).²
15
16
17
18
19
20
21

22 The total syntheses of teixobactin³⁻⁴ and its analogues⁵⁻⁷ and their biological activities have
23
24 been published in the past year. We⁶ and others^{5, 7} have reported the synthesis of Arg₁₀-
25
26 teixobactin by replacing the synthetically challenging enduracididine amino acid at position
27
28 10 with arginine. We have reported the first structure activity relationships (SAR) of Arg₁₀-
29
30 teixobactin and established the importance D amino acids for antibacterial activity.^{4, 6-8} In
31
32 previous work, we also elucidated the 3D molecular structures of teixobactin analogues. The
33
34 disordered structure of teixobactin analogues was found to be vital for their biological activity,
35
36 D-Gln₄ being essential and *D-allo*-Ile₅ being important to maintain the disordered structure.
37
38 However, the replacement of D-Gln₄ and *D-allo*-Ile₅ with L counterparts provided a more
39
40 ordered structure of teixobactin.⁹
41
42
43
44
45
46
47
48

49 The minimum pharmacophore of teixobactin was reported by Nowick et al.⁷ A lysine scan of
50
51 Arg₁₀-teixobactin was reported by the Albericio group.⁸ Replacement of any of the four
52
53 isoleucine residues with lysine led to a complete loss of activity. The replacement of Ser₃,
54
55
56
57
58
59
60

1
2 Gln₄ and Ala₉ by lysine was tolerated well and biological activity was maintained. The
3
4 replacement of cationic residues such as arginine or lysine at position 10 with histidine led to
5
6 inferior biological activity.¹⁰
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Teixobactin and its key analogues containing cationic amino acid at position 10



Teixobactin analogues containing hydrophobic amino acid at position 10








Figure 1. Teixobactin and its analogues containing cationic and hydrophobic amino acids. Cationic analogues A²⁻⁴, B^{5-6, 11}, C^{7, 11}, D¹¹⁻¹², E¹³ and hydrophobic analogues F¹⁴, G¹⁴, H¹⁴, I¹⁴, J¹⁴ (D amino acids highlighted in red and the position 10 amino acids are highlighted in blue).

The *L-allo*-enduracididine was reported to be important for high antibacterial potency of teixobactin.³ However, it is also a key bottleneck in the production and development of

1
2 teixobactin analogues due to various synthetic challenges.¹⁵ We have reported the design and
3
4 synthesis of potent teixobactin analogues against MRSA through the isosteric replacement of
5
6
7 *L-allo*-enduracididine.¹¹ Recently, Brimble and coworkers reported the synthesis of
8
9
10 teixobactin analogues through replacement of *L-allo*-enduracididine with amino acid
11
12
13 isosteres and evaluated biological activity against MRSA and VRE.¹²
14
15
16
17
18

19
20 To expedite access to highly potent teixobactin analogues, we recently reported a new design
21
22 by replacing the synthetically challenging enduracididine with commercially available
23
24 hydrophobic residues such as leucine and isoleucine.¹⁴ Leu₁₀- teixobactin and Ile₁₀-
25
26
27 teixobactin showed identical activity to teixobactin against MRSA *in vitro*. However,
28
29
30 increased hydrophobicity may have an adverse influence on the *in vivo* capacity to be further
31
32
33 developed as therapeutic drugs. Teixobactin and key teixobactin analogues and their
34
35
36 antibacterial activities are summarised in figure 1.
37
38
39
40

41
42 Teixobactin has shown antibacterial efficacy *in vivo* in three mouse models of infection.
43
44 Although these results are encouraging, a significant amount of work remains in the
45
46 development of teixobactin as a therapeutic antibiotic for human use.¹⁵ The translation of
47
48
49 molecules from a discovery phase to useful therapeutic antibiotics is prone to high failure due
50
51
52 to numerous challenges, such as balancing high efficacy *in vivo* against a broad spectrum of
53
54
55 pathogens with minimal liabilities against human targets and the balancing of hydrophobicity
56
57
58
59
60

1
2 with hydrophilicity to address water solubility issues.¹⁶ There is a pressing need for highly
3
4 potent analogues of teixobactin to address common drug development challenges. To date,
5
6 there have been no *in vivo* evaluation studies of teixobactin analogues.
7
8
9

10
11
12 To address such teixobactin development challenges, we report herein the design and
13
14 synthesis of 10 highly potent teixobactin analogues (Figure 2) and their antibacterial
15
16 evaluations against *S. aureus*, MRSA, VRE and *in vivo* evaluation of one analogue in a mice
17
18 model of *S. aureus* keratitis. This work lays the foundation for the development of *in vivo*
19
20 ready teixobactin analogues.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2. Structure of teixobactin analogues 1-10.

Results and discussion

Design and synthesis:

To date, teixobactin is the only molecule in its class which has shown *in vivo* antibacterial efficacy. To realise the therapeutic potential of molecules based on the teixobactin scaffold, there is a pressing need for *in vivo* ready, simplified teixobactin analogues with ease of access to address the current challenges associated due to the lengthy and daunting total synthesis of teixobactins.

In this work, to address such teixobactin development challenges, we speculated that replacement of Ser₃, D-Gln₄ and Ala₉ of Leu₁₀-teixobactin and Ile₁₀-teixobactin with cationic arginine would mimic a suitable balance of hydrophobicity and hydrophilicity similar to natural teixobactin. We thus replaced the Ser₃, D-Gln₄ and Ala₉ of Leu₁₀-teixobactin and Ile₁₀-teixobactin with arginine in a systematic fashion (**1-10**, Figure 2). In this way, we realized an optimal balance between hydrophobicity and hydrophilicity. Six of these analogues (**1-3**, **8-10**, Figure 2) have a hydrophobic-hydrophilic profile (two positive charges at physiological pH) similar to natural teixobactin. Three analogues (**4-6**, Figure 2) feature three positive charges and one analogue (**7**, Figure 2) bears four positive charges. In total, we synthesised 10 new and highly potent teixobactin analogues (Figure 2, **1-10**) in a similar fashion to our recently reported highly efficient strategy (scheme 1 and experimental section).¹⁴



Scheme 1. Synthesis of D-Arg₄-Leu₁₀-teixobactin starting from 2-chlorotrytylchloride resin: a. 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM, 3h. b. 20% piperidine in DMF followed by 3 eq. AllocHN-D-Thr-OH, 3 eq. HATU/6 eq. DIPEA, 1.5h. c. 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2h followed by capping with Ac₂O/DIPEA 10% in DMF, 20% piperidine in DMF. d. 4 eq. Fmoc-Leu-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1h followed by 20% piperidine in DMF. e. 10 eq. Trt-Cl, 15% Et₃N in DCM, 1h. f. 0.2 eq. [Pd(PPh₃)₄]⁰ + 24 eq. PhSiH₃ in dry DCM, 1 x 20 min, 1 x 45 min. g. 4 eq. Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting group), 4 eq. DIC/Oxyma (μwave, 10 min) followed by 20% piperidine in DMF (3 min, 10 min). h. TFA:TIS:DCM = 2:5:93, 1h. i. 1 eq. HATU/10 eq. DIPEA in DMF, 30 min. j. TFA:TIS:H₂O = 95:2.5:2.5, 1h.

Table 1. List of teixobactin analogues (**1-12**). MIC: Minimum Inhibitory Concentration. *MRSA ATCC 33591 used.

Compound	Name	MIC* ($\mu\text{g/mL}$)
1	Arg ₃ -Leu ₁₀ -teixobactin	0.125
2	D-Arg ₄ -Leu ₁₀ -teixobactin	0.125
3	Arg ₉ -Leu ₁₀ -teixobactin	0.125
4	Arg ₃ -D-Arg ₄ -Leu ₁₀ -teixobactin	0.25
5	Arg ₃ -Arg ₉ -Leu ₁₀ -teixobactin	1
6	D-Arg ₄ -Arg ₉ -Leu ₁₀ -teixobactin	1
7	Arg ₃ -D-Arg ₄ -Arg ₉ -Leu ₁₀ -teixobactin	1
8	Arg ₃ -Ile ₁₀ -teixobactin	0.25
9	D-Arg ₄ -Ile ₁₀ -teixobactin	0.125
10	Arg ₉ -Leu ₁₀ -teixobactin	0.25
11	Leu ₁₀ -teixobactin	0.25
12	Teixobactin	0.25

***In vitro* antibacterial studies:**

The antimicrobial potency of teixobactin analogues **1-10** was assessed against MRSA ATCC 33591. The Leu₁₀-teixobactin and natural teixobactin were included as benchmarks for activity. The six analogues **1-3**, **8-10** with two cationic charges have hydrophobic-hydrophilic balances similar to natural teixobactin (two cationic charges). These analogues showed comparable potency (MIC 0.125 - 0.25 $\mu\text{g/ml}$) to natural teixobactin (MIC 0.25 $\mu\text{g/ml}$, Table 1). The three analogues **4-6** each possess three cationic charges. Interestingly, analogue **4** showed comparable antimicrobial activity (MIC 0.25 $\mu\text{g/ml}$) to natural teixobactin. However, analogues **5** and **6** showed 4 times reduced antibacterial activity (MIC 1 $\mu\text{g/ml}$) than natural

1
2 teixobactin or Leu₁₀-teixobactin. The analogue **7** with four cationic charges also showed
3
4 reduced antibacterial activity (MIC 1 μ g/ ml).
5
6
7
8
9

10 The teixobactin analogues **1-10** were further assessed against a panel of antibiotic-resistant
11 and antibiotic susceptible Gram-positive pathogens and comparator antibiotics, daptomycin
12 (Figure 3). The MIC results indicate that the synthetic analogues are potent against the various
13 strains tested, but their MIC distribution differs significantly. Interestingly, we observed a
14 wider distribution of MIC values as the overall net charge of the peptide was increased (Table
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 and 2).

Notably, the MIC values for *Staphylococcus* were not altered whereas a significant increase
in *Enterococcus* was observed with four cationic charges (**7**, MIC 2-8 μ g/ ml). Similar trends
have been reported for teixobactin analogues, whereby increases in positive charges give
increases in MICs against *Staphylococcus aureus* ATCC 29213.¹³ Herein, for example, Lys₃-
D-Lys₄-Lys₁₀-teixobactin (four cationic charges, Figure1E) has a reported MIC of 8 μ g/ ml
against *Staphylococcus aureus* ATCC 29213,¹³ whereas, we observed an MIC of 1 μ g/ ml (8
times improvement) for Arg₃-D-Arg₄-Arg₉-Leu₁₀-teixobactin **7** (four cationic charges,
Figure2) against the same bacterial strain.

The inclusion of 3 arginines in the above case likely perturbs the amphiphilic character of the
teixobactin, resulting in a decrease in activity. The six analogues **1-3**, **8-10** with two cationic
charges showed comparable antibacterial potency to Leu₁₀-teixobactin. Importantly, the

1 hydrophobic-hydrophilic balance of these analogues was similar to natural teixobactin (two
 2 cationic charges). The analogues **4-6** with three cationic charges also showed comparable
 3 antibacterial potency to Leu₁₀-teixobactin. All synthesized analogues showed good potency
 4 against a broad panel of bacteria. The nine analogues **1-6**, and **8-10** showed drug like profiles
 5 such as high antibacterial potency with optimal balance of hydrophobicity and hydrophilicity.
 6 We have further determined the minimum bactericidal concentrations (MBC) of teixobactin
 7 analogues against *S. aureus*/MRSA strains (Table S3). Compound **2** displayed highly potent
 8 bactericidal properties, as its MBC values did not increase above 4 times the MIC against the
 9 tested strains. Compound **2** was found inactive against *Pseudomonas aeruginosa* (Gram
 10 negative bacteria, table S2). In view of narrow MIC distribution values and bactericidal
 11 properties, we focused our attention on compound **2** and further investigated its biological
 12 properties.




Figure 3 MIC distribution of various analogues of teixobactin (**1-10**) against 19 different Gram-positive pathogens (Table S2). The teixobactin analogues, daptomycin (labelled as **D**) was used as the comparator drug. Note the increase in MIC distribution as the overall net charge on the teixobactin analogues was increased. The number in parenthesis indicates the overall net charge of the peptides.

Table 2. MIC values of compounds **1-10** against a broad panel of bacteria. *Enterococcus faecalis*, VRE 1001-1002, 1004, 1008 are clinical isolates. MRSA 42412, MRSA 21455 and MRSA 1003 are clinical isolates.

	Compound → No.	1	2	3	4	5	6	7	8	9	10	11
	Strain ↓											
1.	<i>Staphylococcus saprophyticus</i> ATCC BAA 750	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	-
2.	<i>Staphylococcus saprophyticus</i> ATCC 15305	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	0.25	<0.0625	<0.0625	<0.0625	-
3.	<i>Staphylococcus saprophyticus</i> ATCC 49453	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	-
4.	<i>Staphylococcus saprophyticus</i> ATCC 49907	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	-
5.	VRE 1001	0.25	0.5	0.5	1	0.5	1	2	1	0.5	1	-
6.	VRE 1002	0.5	1	1	1	1	1	8	1	1	1	-
7.	VRE 1004	<0.0625	0.25	0.25	0.5	0.5	1	4	1	0.5	1	-
8.	VRE 1008	0.125	0.5	0.25	0.5	0.5	1	8	1	0.5	1	-
9.	VRE ATCC 700802	0.5	0.5	0.5	2	1	1	4	1	0.25	1	0.25
10.	VRE ATCC 29212	0.5	0.5	1	1	1	1	4	1	0.25	1	0.25
11.	MRSA ATCC 700699	0.5	0.25	0.5	0.5	1	1	2	1	0.25	1	0.25
12.	MRSA 42412	<0.0625	0.0313	<0.0625	0.25	0.25	1	2	0.125	<0.0625	0.125	<0.0625
13.	MRSA 21455	0.03125	0.0313	0.25	0.5	1	1	2	0.25	0.03125	0.5	<0.0625
14.	MRSA 1003	<0.0625	0.5	0.25	1	2	0.5	2	0.125	<0.0625	0.5	-
15.	SA29213	0.25	<0.0625	0.5	0.25	1	1	1	0.5	0.0625	1	-
16.	SA4299	0.125	-	0.25	0.25	0.5	0.5	1	0.125	<0.0625	1	-
17.	SE12228	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	-
18.	<i>Bacillus Cereus</i> ATCC 11788	<0.0625	0.5	0.25	1	1	1	1	0.125	<0.0625	0.5	-
19.	<i>Bacillus Subtilis</i> ATCC 6633	<0.0625	0.125	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	<0.0625	0.125	-

Resistance studies and time dependent killing of bacteria using teixobactin analogue **2**:

D-Arg₄-Leu₁₀-teixobactin (**2**) was evaluated for single step resistance in *S. aureus* ATCC 29213 and MRSA ATCC 33591. We were unable to obtain mutants of *S. aureus* ATCC 29213 or MRSA ATCC 33591 resistant to teixobactin analogue **2** (5x, 10x, 20x MIC). The calculated frequency of resistance to teixobactin analogue **2** was found to be $<10^{-10}$ (SI page S17) which is comparable to teixobactin.² A lack of resistance in preliminary studies against **2** is promising in the development of drug like molecules against resistant bacteria.

Time-kill kinetics studies of D-Arg₄-Leu₁₀-teixobactin **2** against *S. aureus* ATCC 29213 was investigated to ascertain if the chemical modifications retained the bactericidal properties. The exposure of bacterial inoculum to 0.5 $\mu\text{g/ml}$ or 1 $\mu\text{g/ml}$ of compound **2** resulted in ≥ 2 log₁₀ decrease in bacterial viability at 8 h (Figure S24), which is comparable with previous reports of teixobactin analogues and teixobactin.^{2, 14}

***In vitro* cytotoxicity studies:**

It was important to evaluate the cytotoxicity of compound **2** on mammalian cells prior to *in vivo* studies. We determined the cytotoxicity of **2** in human lung epithelial cell line A549 and primary dermal fibroblasts (hDFs). Both of these cell culture models are already established for evaluation of cytotoxicity of antimicrobial peptides.¹⁷⁻¹⁸ An MTS assay indicated that both mammalian cell-types exposed to various concentrations of the peptide retained significant metabolic activity ($\geq 80\%$ viability, Figure 4 a,b), even at a concentration that was ~ 900 times (250 $\mu\text{g/ml}$) higher than the average MIC (0.27 $\mu\text{g/ml}$) values, indicating excellent cell

selectivity of the teixobactin analogues. High content images indicated the absence of any cytoskeletal and nuclear disruption upon exposure of both epithelial and fibroblasts cells to compound **2** (Figure 4 c,d), establishing its non-cytotoxic properties. The morphology of mammalian cells exposed to **2** appeared similar to the untreated cells. However, exposure of cells to an antineoplastic agent (nocodazole, used as a control) resulted in substantial loss of adhered cells, confirming its cytotoxicity.




Figure 4. Cytotoxicity evaluation of **2** in A549 lung epithelial cell line and human primary dermal fibroblasts (hDFs). Both A549 cells (a) and hDFs (b) were treated with increasing concentrations of **2** (ranging from 15.62 $\mu\text{g/ml}$ to 250 $\mu\text{g/ml}$) for 24 h. The stock solution of **2** (500 $\mu\text{g/ml}$) was prepared fresh by directly dissolving **2** in cell culture medium and used. Cells were treated with dimethyl sulfoxide (DMSO, 0.1% v/v)

1
2 or nocodazole (5 $\mu\text{g}/\text{ml}$ dissolved in DMSO) as controls. At the end of the treatment period, metabolic
3
4 activities of cells were quantified by MTS-based cell viability assay. Data represents mean \pm SEM of three
5
6 independent triplicate experiments, * $p > 0.05$. After 24 h treatment with **2**, A549 cells (c) and hDFs (d) were
7
8 fixed, fluorescently stained with rhodamine-phalloidin (red), alexa fluor 488 conjugated anti- α -tubulin
9
10 (green) and Hoechst 33342 (blue) and imaged using IN Cell Analyzer 2200 automated microscope.
11
12 Representative images of cells treated with **2** (62.5 $\mu\text{g}/\text{ml}$ for 24 h) or nocodazole (10 $\mu\text{g}/\text{ml}$, toxicity control)
13
14 are shown.
15
16
17

18 19 20 21 ***In vivo* toxicity studies:**

22
23
24 We examined the *in vivo* toxicity of **2** in a rabbit corneal damage model. A 50 μl of 0.3%
25
26 (w/v) solution was applied topically (4 times/day) to the circularly debrided cornea and re-
27
28 epithelialization was monitored by fluorescein staining. Vehicle alone served as control.
29
30 Figure 5 shows the decrease in fluorescein staining with time for both control wounds and
31
32 wounds treated with **2**. There was no significant difference in wound closure between PBS-
33
34 treated wounds or wounds treated with **2** (Figure S25). The lack of any delay in the re-
35
36 epithelialization and wound closure for the injured cornea treated with **2** suggests good
37
38 biocompatibility of the peptide.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Representative slit lamp fluorescence images showing the time-dependent changes in wound closure of the cornea after application of PBS (2 eyes) or 0.3% peptide **2** (4 eyes). The wounded cornea was stained fluorescein to observe epithelial defects and imaged by slit lamp biomicroscopy.

***In vivo* antibacterial efficacy of D-Arg₄-Leu₁₀-teixobactin in bacterial keratitis model:**

We examined the *in vivo* efficacy of peptide **2** in the mice-eye model of *S.aureus* keratitis. *S. aureus* is one of the major etiological agents for bacterial keratitis and the toxic secretions produced by this microorganism have been implicated in corneal melt, leading to significant morbidity and vision loss.¹⁹⁻²⁰ Scarified cornea of the mice were infected with *S. aureus* ATCC 29213 inoculum (15 μ l of 6×10^6 CFU/ml). At 6 h post infections (p.i.), the infected cornea were treated with vehicle (PBS), peptide **2** (0.3% w/v in PBS) and moxifloxacin (0.3%). A total of 8 doses were applied and the progression of the infection was monitored by slit lamp examination, anterior segment optical coherent tomography (AS-OCT) and microbiological enumeration of the bacterial bioburden. Mice cornea treated with PBS had severe clinical presentation indicated by chemosis, significant presence of hypopyon like materials and corneal infiltrates (Figure 6).




Figure 6 Slit lamp examination of mice infected with *S. aureus* ATCC 29213 strains. After scratching the corneal epithelium with scalpel blade, the scarified cornea was infected with a bacterial inoculum of 6×10^6 CFU/ml ($15 \mu\text{l/cornea}$). At 6 h post infections, the infected cornea were treated with $15 \mu\text{l}$ of PBS, peptide **2** (0.3% w/v in PBS) and moxifloxacin (0.3% w/v in PBS). Note the significant presence of corneal haze and mucopurulent discharge in PBS treated cornea whereas peptide **2** or moxifloxacin treated cornea remained clear and no signs of corneal defects.

Notably, infected cornea treated with peptide **2** or a fluoroquinolone antibiotic, had similar clinical appearance presentation, as indicated by lack of any conjunctival chemosis and corneal infiltrates. These results indicate that peptide **2** halted the progression of *S. aureus* infections and the activity was comparable to moxifloxacin. To determine the effect of treatments on tissue severity, we determined the corneal thickness from various groups (Figure 7a, Figure S26). The baseline corneal thickness of mice ($93.8 \pm 2.9 \mu\text{m}$) decreased moderately ($79.0 \pm 3.4 \mu\text{m}$) after de-epithelialization followed by *S. aureus* infection (6h p.i.). Treatment of the infected cornea with vehicle alone (PBS) resulted in substantial increase in corneal thickness after 24 h ($151.7 \pm 12.7 \mu\text{m}$) and 48 h ($186.2 \pm 17.5 \mu\text{m}$), indicating corneal edema after infection. Infected cornea treated with peptide **2** had a mean corneal thickness of

92.3±12.5 μm and 121.7±3.2 μm after 24 h and 48 h post treatment (p.t.), respectively. For the moxifloxacin-treated cornea the mean corneal thickness was 124.2±9.4 μm after 24 h p.t. and 140.3±10.3 μm after 48 h p.t. These results suggested that peptide **2** treatment resulted in significant decrease in corneal edema after *S. aureus* infections when compared PBS treated or moxifloxacin-treated groups.




Figure 7. a) Changes in corneal thickness (CT) of mice before and after infections and treatment with various groups. Note that the CT values for peptide **2** treated cornea approached the baseline values after 48 h p.t., which was absent in the case of PBS-/Moxifloxacin-treated corneas. Note that a significant decrease in corneal edema was observed for infected cornea treated with peptide **2** compared to untreated cornea (p, 0.01 two-way ANOVA) as early after 3 doses which decreased further after 8 doses (p, 0.001). The results indicated a marked decrease in the severity (due to infections) after treatment with **2** when compared to standard antibiotic treatment. b) Bacterial bioburden in the infected corneal after 48 h treatment with various groups. Values represent colony counts from individual cornea and bars represent mean CFU/tissue \pm standard errors of the mean.

1
2
3 Bacterial enumeration of the corneal tissues harvested after 8 dosages confirmed the *in vivo*
4 efficacy of peptide **2** (Figure 7b). All the infected cornea that received PBS treatment
5
6
7
8
9 contained significant presence of bacteria, varying from $4.7 \times 10^5 - 1.3 \times 10^7$ CFU/tissue. The
10
11
12 mean \log_{10} CFU/tissue \pm standard error of the mean for PBS treated cornea was 6.51 ± 0.27 .
13
14 Five out of six cornea treated with peptide **2** had detectable bacterial colonies. The mean \log_{10}
15
16
17 CFU/tissue for peptide **2** treated cornea was 3.97 ± 0.19 . Four infected corneas treated with
18
19
20 moxifloxacin contained detectable bacterial colonies with a mean \log_{10} CFU/tissue of
21
22
23 3.7 ± 0.24 was observed. These results confirmed that peptide **2** had a similar antibacterial
24
25
26 effect as an established antibiotic in decreasing the bacterial bioburden, thus demonstrating
27
28 its potential as a safe therapeutic for topical applications.
29
30
31
32

33 **Conclusion**

34
35
36 In conclusion, we have designed and synthesized 10 novel analogues of teixobactin through
37
38
39 the selective replacement of Ser₃, D-Gln₄ and Ala₉ residues by D/L arginines in Leu₁₀-
40
41
42 teixobactin and Ile₁₀-teixobactin. We have successfully achieved a fine balance of
43
44
45 hydrophobicity and hydrophilicity while maintaining high antibacterial potency both *in vitro*
46
47
48 and *in vivo*. Importantly, most of these teixobactin analogues showed highly potent
49
50
51 antibacterial activity against *S. aureus*, MRSA, and VRE comparable to Leu₁₀-teixobactin
52
53
54 and Ile₁₀-teixobactin. The MIC values on a broad panel of Gram-positive bacteria indicate a
55
56
57
58
59
60

1
2 direct correlation between overall net charge and a narrow distribution of MIC values; for
3
4 example, a wider distribution of MIC results as the overall net charge of the peptide increases.
5
6
7
8
9

10 The teixobactin-based peptide analogue **2** was found non-cytotoxic both *in vitro* and *in vivo*.
11
12 In a mice model of infectious keratitis, the topical instillation of **2** resulted in >99.0%
13
14 reduction in bacterial bioburden and the efficacy was comparable to moxifloxacin. Notably,
15
16 *S. aureus* is one of the major etiological agents for bacterial keratitis and has been implicated
17
18 in corneal melt, leading to significant morbidity and vision loss^{15,16}. Furthermore in our
19
20 keratitis mice models, the synthetic teixobactin-analogue **2** decreased corneal edema
21
22 (severity) significantly when compared to untreated cornea or moxifloxacin treated cornea.
23
24
25
26 To the best of our knowledge, this work is the first *in vivo* demonstration of the excellent
27
28 therapeutic potential of a teixobactin analogue in attenuating bacterial infections and
29
30 associated severity. We believe this work represents a significant advancement in the
31
32 development of *in vivo* ready simplified teixobactin analogues. Thus, the design of safe and
33
34 highly potent synthetic peptide analogues of teixobactin presented here will enable the
35
36 development of new drug like analogues against antibiotic-resistant bacterial strains. The
37
38 findings presented in this work have broad implications and are expected to facilitate the
39
40 development of peptide based therapies to combat the serious global challenges posed by
41
42
43
44
45
46
47
48
49
50 AMR.
51
52
53
54
55
56
57
58
59
60

Experimental

Synthesis of D-Arg₄-Leu₁₀-teixobactin (2)

D-Arg₄-Leu₁₀-teixobactin (2) was synthesised as described in **scheme 1** using our previously reported procedure.¹⁴ (step a) Commercially available 2-chlorotriptyl chloride resin (manufacturer's loading = 1.2 mmol/g, 170 mg resin) was swelled in DCM in a reactor. To this resin was added 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM and the reactor was shaken for 3h. The loading determined by UV absorption of the piperidine-dibenzofulvene adduct was calculated to be 0.6 mmol/g, (170mg resin, 0.102 mmol). Any unreacted resin was capped with MeOH:DIPEA:DCM = 1:2:7 by shaking for 1h. (step b) The Fmoc protecting group was deprotected using 20% piperidine in DMF by shaking for 3 min, followed by draining and shaking again with 20% piperidine in DMF for 10 min. AllocHN-D-Thr-OH was then coupled to the resin by adding 3 eq. of the AA, 3 eq. HATU and 6 eq. DIPEA in DMF and shaking for 1.5h at room temperature. (step c) Esterification was performed using 10 eq. of Fmoc-Ile-OH, 10 eq. DIC and 5 mol% DMAP in DCM and shaking the reaction for 2h. This was followed by capping the unreacted alcohol using 10% Ac₂O/DIPEA in DMF shaking for 30 min and Fmoc was removed using protocol described earlier in step (b). (step d) Fmoc-Leu-OH was coupled using 4 eq. of AA, 4 eq. HATU and 8 eq. DIPEA in DMF and shaking for 1h followed by Fmoc deprotection using 20% piperidine in DMF as described earlier. (step e) The N terminus of Leu was protected using 10 eq. Trt-Cl and 15% Et₃N in DCM and shaking for 1h. The protection was verified by the Ninhydrin colour test. (step f) The Alloc protecting group of D-Thr was removed using 0.2 eq. [Pd(PPh₃)]⁰ and 24 eq. PhSiH₃ in dry

1 DCM under argon for 20 min. This procedure was repeated again increasing the time to 45
2
3 min and the resin was washed thoroughly with DCM and DMF to remove any Pd stuck to the
4
5 resin. (step g) All amino acids were coupled using 4 eq. Amino Acid, 4 eq. DIC/Oxyma using
6
7 a microwave peptide synthesizer. Coupling time was 10 min. Deprotection cycles were
8
9 performed as described earlier. (step h) The peptide was cleaved from the resin without
10
11 cleaving off the protecting groups of the amino acid side chains using TFA:TIS:DCM =
12
13 2:5:93 and shaking for 1h. (step i) The solvent was evaporated and the peptide was redissolved
14
15 in DMF to which 1 eq. HATU and 10 eq. DIPEA were added and the reaction was stirred for
16
17 30 min to perform the cyclization. (step j) The side-chain protecting groups were then cleaved
18
19 off using TFA:TIS:H₂O = 95:2.5:2.5 by stirring for 1h. The peptide was precipitated using
20
21 cold Et₂O (-20°C) and centrifuging at 7000 rpm to obtain a white solid. This solid was further
22
23 purified by RP-HPLC using the protocols described in supporting information SII.
24
25

26
27 All teixobactin analogues were synthesised by using the method described above. The overall
28
29 yields after HPLC purifications were typically in the range of 13-22%. All teixobactin
30
31 analogues **1-10** were characterized by HRMS (ESI) in positive mode (see table 3, SII and
32
33 figures S1-S20). Analogue **2** was also characterised by NMR (S IV, table S1, figures S22-
34
35 23.). The homogeneity of HPLC purified fractions were analyzed by mass spectroscopy. All
36
37 the teixobactin analogues used were purified to >95% purity as indicated by HPLC.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3: Compound number, name, chemical formula, mass calculated and mass observed for teixobactin analogues **1-10**.

Compound	Name	Chemical formula	Mass	
			Calcd (Da)	Mass obsd (Da)
1	Arg ₃ -Leu ₁₀ -teixobactin	C ₆₁ H ₁₀₄ N ₁₅ O ₁₄	1270.7887	1270.7913
2	D-Arg ₄ -Leu ₁₀ -teixobactin	C ₅₉ H ₁₀₁ N ₁₄ O ₁₄	1229.7622	1229.7650
3	Arg ₉ -Leu ₁₀ -teixobactin	C ₆₁ H ₁₀₄ N ₁₅ O ₁₅	1286.7836	1286.7843
4	Arg ₃ -D-Arg ₄ -Leu ₁₀ -teixobactin	C ₆₂ H ₁₀₈ N ₁₇ O ₁₃	1298.8313	1298.8325
5	Arg ₃ -Arg ₉ -Leu ₁₀ -teixobactin	C ₆₄ H ₁₁₁ N ₁₈ O ₁₄	1355.8527	1355.8606
6	D-Arg ₄ -Arg ₉ -Leu ₁₀ -teixobactin	C ₆₂ H ₁₀₈ N ₁₇ O ₁₄	1314.8262	1314.8263
7	Arg ₃ -D-Arg ₄ -Arg ₉ -Leu ₁₀ -teixobactin	C ₆₅ H ₁₁₅ N ₂₀ O ₁₃	1383.8952	1383.8943
8	Arg ₃ -Ile ₁₀ -teixobactin	C ₆₁ H ₁₀₄ N ₁₅ O ₁₄	1270.7887	1270.7896
9	D-Arg ₄ -Ile ₁₀ -teixobactin	C ₅₉ H ₁₀₁ N ₁₄ O ₁₄	1229.7622	1229.7607
10	Arg ₉ -Ile ₁₀ -teixobactin	C ₆₁ H ₁₀₄ N ₁₅ O ₁₅	1286.7836	1286.7780

Supporting information

Supplementary Information (ESI) available: Peptides HPLC, LC-MS analysis, NMR analysis, *in vitro* antibacterial assay (MIC, MBC, time kill kinetics), *in vitro* cytotoxicity assay, *in vivo* cytotoxicity assay and *in vivo* antibacterial efficacy.

Acknowledgements

1 Anish Parmar and Abhishek Iyer would like to thank the University of Lincoln for funding.
2
3
4 Edward Taylor would like to thank the Royal Society for their kind support (grant number
5
6 UF100116). Ishwar Singh would like to acknowledge the Royal Society for their kind support
7
8 (grant number (RG130163) and Horizon 2020 (645684)). Daniel Lloyd, Edward Taylor and
9
10
11 Ishwar Singh would like to acknowledge the Rosetrees trust for their kind support (grant
12
13 number JS16/M583). Rajamani Lakshminarayanan would like to acknowledge Co-operative
14
15 Basic Research Grant from Singapore National Medical Research Council (grant number
16
17 NMRC/CBRG/0048/2013). Navin K Verma would like to acknowledge Lee Kong Chian
18
19 School of Medicine, Nanyang Technological University, Singapore Start-Up Grant (grant
20
21 number (L0412290) and the Singapore Ministry of Education Academic Research Fund Tier
22
23 1 (grant number 2015-T1-001-082). Nicholas Riess from University of Lincoln is thanked for
24
25 HRMS. We thank Novobiotic Pharmaceuticals, LLC for generously providing natural
26
27 teixobactin, which was used as a positive control in MIC assays. We also thank Dr Martin J.
28
29 Lear (University of Lincoln) for helpful discussions during the preparation of the manuscript.
30
31
32
33
34
35
36
37
38

39 **Conflict of Interest**

40
41
42 The authors declare no conflict of interest.
43
44
45
46
47

48 **Author contributions**

49
50 Corresponding author isingh@lincoln.ac.uk
51
52

53 † These authors have contributed equally to this work. The project was designed by Ishwar
54
55 Singh with the help of all authors. The manuscript was written by Abhishek Iyer, Anish
56
57
58
59
60

1 Parmar, Rajamani Lakshminarayanan and Ishwar Singh through contributions from all
2 authors. Anish Parmar carried out the teixobactin analogues syntheses. Daniel G. Lloyd, and
3
4
5
6
7 Edward J Taylor have contributed to the antibacterial studies. Madhavi Latha S. Chalasani
8
9
10 and Navin K. Verma carried out the *in vitro* toxicity studies. Annemieke Madder was
11
12 responsible for the LC-MS analyses. Mayandi Venkatesh, Eunice Tze Leng Goh, Roger W.
13
14
15 Beuerman and Rajamani Lakshminarayanan were responsible for the *in vitro* antibacterial
16
17 studies and *in vivo* toxicity and antibacterial studies. All authors have given approval to the
18
19
20 final version of the manuscript.
21

22 **Abbreviations used**

23
24
25
26 AA, Amino acid; Ac₂O, Acetic anhydride; Alloc, Allyloxycarbonyl; AMR, Antimicrobial
27
28 Resistance; ATCC, American Type Cell Culture; Boc, tert-butyloxycarbonyl; CFU, Colony-
29
30 forming Unit; DCM, Dichloromethane; DIC, Diisopropylcarbodiimide; DIPEA/DIEA,
31
32 diisopropylethylamine; DMAP, 4-Dimethylaminopyridine; DMF, *N,N*-
33
34 Dimethylformamide; Et₃N, Triethylamine; ESI, Electrospray Ionization; HATU, *N*-
35
36 [(dimethylamino-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl)methylene]-*N*-methylmethanaminium
37
38 hexafluorophosphate *N*-oxide; hDFs, Human Dermal Fibroblasts; HRMS, High Resolution
39
40 Mass Spectroscopy, HPLC, High-performance Liquid Chromatography; MeOH,
41
42 Methanol; MIC, Minimum Inhibitory Concentration; MRSA, Methicillin-resistant
43
44 *Staphylococcus aureus*; NMR, Nuclear Magnetic Resonance; *P. aeruginosa*,
45
46 *Pseudomonas aeruginosa*; PBS, Phosphate Buffered Saline; [Pd(PPh₃)₄]⁰,
47
48 Tetrakis(triphenylphosphine)palladium(0); PG, Protecting Group; PhSiH₃, Phenylsilane; *S.*
49
50
51
52
53
54
55
56
57
58
59
60

1
2 *aureus* (SA), *Staphylococcus aureus*; TFA, Trifluoroacetic acid; TIS, Triisopropylsilane; Trt,
3
4 Trityl; VRE, Vancomycin-resistant Enterococci
5
6
7
8
9

10 **References:** (1) *AMR Review*, <http://amr-review.org>, accessed Dec 11 2017.
11

12 (2) Ling, L. L.; Schneider, T.; Peoples, A. J.; Spoering, A. L.; Engels, I.; Conlon, B. P.;

13
14 Mueller, A.; Schaberle, T. F.; Hughes, D. E.; Epstein, S.; Jones, M.; Lazarides, L.;

15
16 Steadman, V. A.; Cohen, D. R.; Felix, C. R.; Fetterman, K. A.; Millett, W. P.; Nitti, A. G.;

17
18 Zullo, A. M.; Chen, C.; Lewis, K. A new antibiotic kills pathogens without detectable
19
20

21
22 resistance. *Nature* **2015**, *517*, 455-459.
23
24
25

26 (3) Giltrap, A. M.; Dowman, L. J.; Nagalingam, G.; Ochoa, J. L.; Linington, R. G.; Britton,

27
28 W. J.; Payne, R. J. Total synthesis of teixobactin. *Org. Lett.* **2016**, *18*, 2788-2791.
29
30

31 (4) Jin, K.; Sam, I. H.; Po, K. H. L.; Lin, D. a.; Ghazvini Zadeh, E. H.; Chen, S.; Yuan, Y.;

32
33 Li, X. Total synthesis of teixobactin. *Nature Communications* **2016**, *7*, 12394.
34
35
36

37 (5) Jad, Y. E.; Acosta, G. A.; Naicker, T.; Ramtahal, M.; El-Faham, A.; Govender, T.;

38
39 Kruger, H. G.; Torre, B. G. d. l.; Albericio, F. Synthesis and biological evaluation of a
40
41

42 teixobactin Analogue. *Org. Lett.* **2015**, *17*, 6182-6185.
43
44

45 (6) Parmar, A.; Iyer, A.; Vincent, C. S.; Van Lysebetten, D.; Prior, S. H.; Madder, A.;

46
47 Taylor, E. J.; Singh, I. Efficient total syntheses and biological activities of two teixobactin
48
49

50 analogues. *Chem. Commun.* **2016**, *52*, 6060-6063.
51
52

53 (7) Yang, H.; Chen, K. H.; Nowick, J. S. Elucidation of the teixobactin pharmacophore.
54
55

56 *ACS Chemical Biology* **2016**, *11*, 1823-1826.
57
58
59
60

- 1
2 (8) Abdel Monaim, S. A. H.; Jad, Y. E.; Ramchuran, E. J.; El-Faham, A.; Govender, T.;
3
4 Kruger, H. G.; de la Torre, B. G.; Albericio, F. Lysine scanning of Arg10–teixobactin:
5
6 deciphering the role of hydrophobic and hydrophilic residues. *ACS Omega* **2016**, *1*, 1262-
7
8 1265.
9
10
11
12 (9) Parmar, A.; Prior, S. H.; Iyer, A.; Vincent, C. S.; Van Lysebetten, D.; Breukink, E.;
13
14 Madder, A.; Taylor, E. J.; Singh, I. Defining the molecular structure of teixobactin
15
16 analogues and understanding their role in antibacterial activities. *Chem. Commun.* **2017**, *53*,
17
18 2016-2019.
19
20
21
22 (10) Wu, C.; Pan, Z.; Yao, G.; Wang, W.; Fang, L.; Su, W. Synthesis and structure-activity
23
24 relationship studies of teixobactin analogues. *RSC Advances* **2017**, *7*, 1923-1926.
25
26
27
28 (11) Parmar, A.; Iyer, A.; Lloyd, D. G.; Vincent, C.; Prior, S. H.; Madder, A.; Taylor, E. J.;
29
30 Singh, I. "Syntheses of potent teixobactin analogues against methicillin-resistant
31
32 *Staphylococcus aureus* (MRSA) through the replacement of L-allo-enduracididine with its
33
34 isosteres". *Chem. Commun.* **2017**, *53*, 7788–7791.
35
36
37
38 (12) Schumacher, C. E.; Harris, P. W. R.; Ding, X.-B.; Krause, B.; Wright, T. H.; Cook, G.
39
40 M.; Furkert, D. P.; Brimble, M. A. Synthesis and biological evaluation of novel teixobactin
41
42 analogues. *Organic & Biomolecular Chemistry* **2017**, *15*, 8755-8760.
43
44
45
46 (13) Abdel Monaim, S. A. H.; Ramchuran, E. J.; El-Faham, A.; Albericio, F.; de la Torre, B.
47
48 G. Converting teixobactin into a cationic antimicrobial peptide (AMP). *J. Med. Chem.* **2017**,
49
50 *60*, 7476-7482.
51
52
53
54
55
56
57
58
59
60

- 1
2 (14) Parmar, A.; Iyer, A.; Prior, S. H.; Lloyd, D. G.; Leng Goh, E. T.; Vincent, C. S.;
3
4 Palmai-Pallag, T.; Bachrati, C. Z.; Breukink, E.; Madder, A.; Lakshminarayanan, R.;
5
6 Taylor, E. J.; Singh, I. Teixobactin analogues reveal enduracididine to be non-essential for
7
8 highly potent antibacterial activity and lipid II binding. *Chemical Science* **2017**, *8*, 8183-
9
10 8192.
11
12
13
14
15 (15) Fiers, W. D.; Craighead, M.; Singh, I. Teixobactin and its analogues: a new hope in
16
17 antibiotic discovery. *ACS Infectious Diseases* **2017**, *3*, 688–690.
18
19
20
21 (16) Hughes, D.; Karlén, A. Discovery and preclinical development of new antibiotics.
22
23 *Upsala Journal of Medical Sciences* **2014**, *119*, 162-169.
24
25
26 (17) Le, C.-F.; Yusof, M. Y. M.; Hassan, H.; Sekaran, S. D. In vitro properties of designed
27
28 antimicrobial peptides that exhibit potent antipneumococcal activity and produces
29
30 synergism in combination with penicillin. *Scientific Reports* **2015**, *5*, 9761.
31
32
33
34 (18) Wu, X.; Wang, Z.; Li, X.; Fan, Y.; He, G.; Wan, Y.; Yu, C.; Tang, J.; Li, M.; Zhang,
35
36 X.; Zhang, H.; Xiang, R.; Pan, Y.; Liu, Y.; Lu, L.; Yang, L. In vitro and in vivo activities of
37
38 antimicrobial peptides developed using an amino acid-based activity prediction method.
39
40 *Antimicrob. Agents Chemother.* **2014**, *58*, 5342-5349.
41
42
43
44
45 (19) Mah, F. S.; Davidson, R.; Holland, E. J.; Hovanesian, J.; John, T.; Kanellopoulos, J.;
46
47 Shamie, N.; Starr, C.; Vroman, D.; Kim, T. Current knowledge about and recommendations
48
49 for ocular methicillin-resistant *Staphylococcus aureus*. *Journal of Cataract & Refractive*
50
51 *Surgery* **2014**, *40*, 1894-1908.
52
53
54
55
56
57
58
59
60

1
2 (20) Henry, C. R.; Flynn, H. W., Jr.; Miller, D.; Forster, R. K.; Alfonso, E. C. Infectious
3
4
5 keratitis progressing to endophthalmitis. *Ophthalmology* **2012**, *119*, 2443-2449.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of contents graphic

